

JUL 0 8 2004]

EXPRESS MAIL NO. EV335394085US

TECH CENTER 1800

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Jiangchun Xu et al.

Application No.

09/593,793

Filed

June 13, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF PROSTATE CANCER

Examiner

: David J. Blanchard

Art Unit

1642

Docket No.

210121.427C15

Date

June 30, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 CFR 1.98, are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Sixth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeffrey-Hundley, Ph.D., Patent Agent

Registration No. 42,676

JEH:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 Cited References (5)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\494462

		110.21000,1000								-
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE			ATTY, DOCKET NO. APPLICATION NO.							
(Da)				210121.427C15 09/593,793						
016	- '03	SIXTH SUPPLEMI	APPLICANTS							
INFO	ORIGI	TION DISCLOSU	Jiangchun Xu et al.							
302	יי ייטו	(Use several sheets if nec	FILING DATE	GROUP ART UNIT						
30	&	<u>/</u>	June 13, 2000		1642	JUL	0 8 200	1		
TENTE THANK	MARIT		U.S.	PATENT 1	DOCUMENTS			TECH CEN		
*EXAMINER • INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ss s	UBCLASS	ER-16007 IF APPRO	
	АА									
•	АВ									
	AC									
	AD									
	AE									
	AF									
	AG	· · · · · · · · · · · · · · · · · · ·								
			FOREI	GN PATE	NT DOCUMENTS			··		
<u> </u> -	<u> </u>	DOCUMENT			COUNTRY			ATION		
		NUMBER	DATE		COUNTRY				YES	NO
	AK									
	AL									
	AM									
		ОТНЕ	R PRIOR A	RT (Including	; Author, Title, Date, Pertinent Pa	ges, Etc.,)			
* 41 = 177	AP	Aspinall, J.O	et al., "Dif	ferential Ex	xpression of Apolipopr	otein-	D and	Prostate	Specif	ic
		Antigen in Benign and Malignant Prosta		ostate Tissues," Journal of Urology 154: 622-62				22-628,	•	
		August 1996	August 1996.							
	AQ	Fannon, M.R., "Gene expression in normal and disease states – identification of therap targets," <i>Trends in Biotechnology 14</i> : 294-298, August 1996.							eutic	
	A.D.	Garde, S.V.	Garde, S.V. et al., "Prostate inhibin peptide (PIP) in prostate cancer: a comparative							
	AR		immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid							
		. 1			s 78: 11-17, 1994.	(, P			
	$\vdash \vdash$					002				
•		Genbank Da	iavase, Acce	581011 INQ.	AA112574, May 29, 20	JU3.				
	. Murphy, G. et al., "Comparison of Prostate Specific Membrane Antigen, and Prostate									
	Specific Antigen Levels in Prostatic Cancer Patients," Anticancer Research 15: 1473-14							1480,		
		1995.								
EXAMINER				DATE CONSIDERED						
* FWALES	CP									
* EXAMIN					informance with MPEP 609. Draw with next communication to appli		ough citat	ion if not in		

KPRESS MAIL NO. EV335394085US

วบท 3 o 2004 8

07-02 04

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

			. 1/
Application	09/593,793		Y
Filing Date	June 13, 2000		
First Named Inventor	Jiangchun Xu	JU 082	MI
Art Unit	1642		700
Examiner Name	David J. Blanchard	TECH CENTER (C	na maa
Attorney Docket No.	210121.427C15		ARRONA

	E	ENCLOSURES (check all that app	(v)		
Extension of TExpress Abarr Request Sixth Supplem Information Destatement; For Statement; For Document(s) Response to Funder 37 C.F. Response to Parts/Incomplements	ral Form ched Response al /declaration(s) Fime Request rdonment mental isclosure form PTO-1449 ences y of Priority Missing Parts R. 1.52 or 1.53		CD(s), Number of CD(s) After Allowance Communication to Technology Center (TC)' Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):		
Remarks					
	SIGNATU	RE OF APPLICANT, ATTORNEY,	OR AGENT		
Individual Name		undley, Ph.D., Patent 'Agent	Customer Number 00500		
Signature					
Date June 30, 200		04			
	CER	TIFICATE OF TRANSMISSION/MA	All ING		
with the United S	at this corresp tates Postal Se	ondence is being facsimile transmit ervice with sufficient postage as first or Patents, P.O. Box 1450, Alexandr	ted to the USPTO or deposited t class mail in an envelope		
Typed or printed	name				
Signature			Date:		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.